Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study

• Status: Terminated
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Keratosis pilaris (KP) is a benign skin condition that often is very frustrating for the patients and treating physicians. The investigators are interested to see if the study product is effective in treating moderate to severe KP.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Wright State University
• Collaborator: Onset Therapeutics
• Treatments: Emollients; Salicylic Acid

Criteria

Inclusion Criteria:

• Subject is willing and able to give informed consent.

• Subject is willing and able to participate in the study as an outpatient and is willing to comply with the study requirements.

• Subject is 18 years of age or older.

• Subject has KP on 2 out of the 4 extremities.

• For each assessed extremity, subject has at least a moderate severity (≥ 3) on the Investigator Site Assessment of KP Severity.

• For each assessed extremity, subject has an aggregate score of at least 6 on the Investigator Assessment of Erythema, Roughness and Scaling.

• If subject is a female of childbearing potential, subject will have a negative urine pregnancy test at screening (week 0).

• If female, subject will be either post-menopausal for > 2 year, surgically sterile (hysterectomy or bilateral tubal ligation), or practicing one form of birth control (abstinence, oral contraceptive, estrogen patch, implant contraception, injectable contraception, IUD, diaphragm, condom, sponge, spermicides, or vasectomy of partner). Female subjects should continue to practice birth control for 1 month after the completion of study.

Exclusion Criteria:

• Subject has evidence of a clinically significant, unstable or poorly controlled medical condition as determined by the investigators/sub-investigators.

• Subject has active skin infection, atopic dermatitis or any other skin disease that will interfere with the clinical assessment of KP.

• Subject has known allergies to any ingredient of study medication.

• Subject who has used any of the following topical therapies for KP lesions within the last two weeks: topical corticosteroid, tretinoin, tazarotene, adapalene, salicylic acid, alpha-hydroxy acid, urea and/or ammonium lactate lotion.

• Subject who has been treated with UVB therapy in the last two weeks.

• Subject who has received systemic antibiotics, steroid, tacrolimus, tretinoin, isotretinoin and/or PUVA within the last 4 weeks.

• Female subjects who are pregnant (positive urine pregnancy test), breast-feeding or are considering become pregnant during the study period.

• Subject who is currently participating in another clinical trial or has completed a clinical trial within the last 4 weeks.